C4X Discovery Holdings

C4X Discovery is a drug discovery company that leverages proprietary technologies, Conformetrix and Taxonomy3, to design small molecule candidates for high-value targets. The company focuses on inflammation, oncology, and neurology, utilizing its platforms to identify novel genetic targets and determine the 3D shapes of molecules to optimize drug design. C4XD operates a partnering-centric business model, progressing programs to a pre-clinical or early clinical stage before out-licensing them to major pharmaceutical companies. Notable partnerships include deals with Sanofi, AstraZeneca, and Indivior. In 2024, the company transitioned from a public listing on the London Stock Exchange to a private entity to better support its long-term growth strategy.